IDH1 and glioblastoma: Besides improved overall survival, Sanson et al. (37) were able to demonstrate improved progressive-free survival (PFS) as well in their set of patients with glioblastoma, with 55 months PFS in patients with IDH1 mutation versus 8.8 months PFS in those without this mutation.